SCLC

[iScience] The authors integrated chromatin landscape and transcriptome analyses of patient-derived small cell lung cancer (SCLC) preclinical models to identify super-enhancers and their associated genes in the ASCL1-, NEUROD1-, and POU2F3-high SCLC subtypes.

[European Respiratory Review] Scientists describe the progress that has been made in systemic treatment by repurposing existing drugs and the addition of targeted treatment.

[Nature Communications] Scientists evaluated 19 protocols for single cell small RNA sequencing on MCF7 cells spiked with 1 pg of 1,006 miRNAs.

[European Journal of Pharmacology] Investigators developed a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated YPN-005, and determined whether it showed any anticancer effects in small cell lung cancer (SCLC), cells, cisplatin or etoposide-resistant cells, or organoids derived from SCLC patients.

[Cancer Immunology, Immunotherapy] To determine the immune-modulatory influence of CSC in small cell lung cancer (SCLC), scientists focused on the characterization of CD44+CD90+ CSC-like subpopulations in SCLC.

[Scientific Reports] Scientists established siRNA-transfected small-cell lung carcinoma cell lines to investigate the anticancer effect of silencing ribonucleotide reductase large subunit gene expression.